Business, energy, technology, markets and global industry news from Business News Today

AVZO-021

PharmaDeviceNews AVZO-021
Infographic highlighting Avenzo’s upcoming December ORION-1 clinical data presentation for AVZO-023, featuring a laboratory illustration and the investigational therapy’s focus on selective CDK4 inhibition and improved tolerability.
Pharma & Biotech

Avenzo Therapeutics to present first ORION-1 Phase 1 data for selective CDK4 inhibitor AVZO-023

Avenzo will present first ORION-1 data for AVZO-023 in December, testing whether selective CDK4 inhibition offers a better tolerability profile.

Read More
Representative image of breast cancer drug development, highlighting Avenzo Therapeutics’ ORION-1 trial of AVZO-023 and AVZO-021 in advanced HR+/HER2- metastatic breast cancer.
Pharma & Biotech

What Avenzo Therapeutics’ ORION-1 expansion reveals about the next phase of CDK drug development

Find out how Avenzo Therapeutics’ AVZO-023 and AVZO-021 combination study could influence HR+/HER2- breast cancer treatment.

Read More
Pharma & Biotech

AVZO-021 at ASCO 2026: what updated Phase 1 results could reveal about Avenzo Therapeutics’ CDK2 strategy

Avenzo Therapeutics will present updated AVZO-021 Phase 1 data at ASCO 2026. Read why the CDK2 story could matter for breast cancer and beyond.

Read More
Pharma & Biotech

Is Avenzo’s AVZO-021 the next big player in HR+/HER2- metastatic breast cancer?

Avenzo shares Phase 1 data on CDK2 inhibitor AVZO-021 in HR+/HER2- breast cancer. Find out what it means for post-CDK4/6 resistance strategies in 2025.

Read More